Defining the Role of Adjuvant Therapy

Cholangiocarcinoma and Gall Bladder Cancer

Terence M. Williams, Lonika Majithia, Samuel Wang, Charles Thomas

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Biliary tract cancers are a rare subgroup of malignancies that include gall bladder carcinoma and cholangiocarcinoma. They generally carry a poor prognosis based on the advanced nature of disease at presentation and overall treatment refractoriness. Surgical resection remains the optimal treatment for long-term survival, with consideration of neoadjuvant or adjuvant therapies. In this review, we summarize the role of adjuvant treatments including radiation therapy, chemotherapy, and concurrent chemoradiation with the existing clinical evidence for each treatment decision. Given the rarity of these tumors, the evidence provided is based largely on retrospective studies, Surveillance, Epidemiological, and End Results (SEER) database inquiries, single- or multi-institutional prospective studies, and a meta-analysis of adjuvant therapy studies. Currently, there is no adjuvant therapy that has been agreed upon as a standard of care. Results from prospective, multi-institutional phase II and III trials are awaited, along with advances in molecular targeted therapies and radiation techniques, which will better define treatment standards and improve outcomes in this group of diseases.

Original languageEnglish (US)
Pages (from-to)94-104
Number of pages11
JournalSeminars in Radiation Oncology
Volume24
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Gallbladder Neoplasms
Cholangiocarcinoma
Therapeutics
Biliary Tract Neoplasms
Molecular Targeted Therapy
Standard of Care
Meta-Analysis
Neoplasms
Urinary Bladder
Radiotherapy
Retrospective Studies
Databases
Prospective Studies
Radiation
Carcinoma
Drug Therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research
  • Medicine(all)

Cite this

Defining the Role of Adjuvant Therapy : Cholangiocarcinoma and Gall Bladder Cancer. / Williams, Terence M.; Majithia, Lonika; Wang, Samuel; Thomas, Charles.

In: Seminars in Radiation Oncology, Vol. 24, No. 2, 2014, p. 94-104.

Research output: Contribution to journalArticle

Williams, Terence M. ; Majithia, Lonika ; Wang, Samuel ; Thomas, Charles. / Defining the Role of Adjuvant Therapy : Cholangiocarcinoma and Gall Bladder Cancer. In: Seminars in Radiation Oncology. 2014 ; Vol. 24, No. 2. pp. 94-104.
@article{e9f59fd229a24eb59a2fe77e13e94310,
title = "Defining the Role of Adjuvant Therapy: Cholangiocarcinoma and Gall Bladder Cancer",
abstract = "Biliary tract cancers are a rare subgroup of malignancies that include gall bladder carcinoma and cholangiocarcinoma. They generally carry a poor prognosis based on the advanced nature of disease at presentation and overall treatment refractoriness. Surgical resection remains the optimal treatment for long-term survival, with consideration of neoadjuvant or adjuvant therapies. In this review, we summarize the role of adjuvant treatments including radiation therapy, chemotherapy, and concurrent chemoradiation with the existing clinical evidence for each treatment decision. Given the rarity of these tumors, the evidence provided is based largely on retrospective studies, Surveillance, Epidemiological, and End Results (SEER) database inquiries, single- or multi-institutional prospective studies, and a meta-analysis of adjuvant therapy studies. Currently, there is no adjuvant therapy that has been agreed upon as a standard of care. Results from prospective, multi-institutional phase II and III trials are awaited, along with advances in molecular targeted therapies and radiation techniques, which will better define treatment standards and improve outcomes in this group of diseases.",
author = "Williams, {Terence M.} and Lonika Majithia and Samuel Wang and Charles Thomas",
year = "2014",
doi = "10.1016/j.semradonc.2014.01.001",
language = "English (US)",
volume = "24",
pages = "94--104",
journal = "Seminars in Radiation Oncology",
issn = "1053-4296",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Defining the Role of Adjuvant Therapy

T2 - Cholangiocarcinoma and Gall Bladder Cancer

AU - Williams, Terence M.

AU - Majithia, Lonika

AU - Wang, Samuel

AU - Thomas, Charles

PY - 2014

Y1 - 2014

N2 - Biliary tract cancers are a rare subgroup of malignancies that include gall bladder carcinoma and cholangiocarcinoma. They generally carry a poor prognosis based on the advanced nature of disease at presentation and overall treatment refractoriness. Surgical resection remains the optimal treatment for long-term survival, with consideration of neoadjuvant or adjuvant therapies. In this review, we summarize the role of adjuvant treatments including radiation therapy, chemotherapy, and concurrent chemoradiation with the existing clinical evidence for each treatment decision. Given the rarity of these tumors, the evidence provided is based largely on retrospective studies, Surveillance, Epidemiological, and End Results (SEER) database inquiries, single- or multi-institutional prospective studies, and a meta-analysis of adjuvant therapy studies. Currently, there is no adjuvant therapy that has been agreed upon as a standard of care. Results from prospective, multi-institutional phase II and III trials are awaited, along with advances in molecular targeted therapies and radiation techniques, which will better define treatment standards and improve outcomes in this group of diseases.

AB - Biliary tract cancers are a rare subgroup of malignancies that include gall bladder carcinoma and cholangiocarcinoma. They generally carry a poor prognosis based on the advanced nature of disease at presentation and overall treatment refractoriness. Surgical resection remains the optimal treatment for long-term survival, with consideration of neoadjuvant or adjuvant therapies. In this review, we summarize the role of adjuvant treatments including radiation therapy, chemotherapy, and concurrent chemoradiation with the existing clinical evidence for each treatment decision. Given the rarity of these tumors, the evidence provided is based largely on retrospective studies, Surveillance, Epidemiological, and End Results (SEER) database inquiries, single- or multi-institutional prospective studies, and a meta-analysis of adjuvant therapy studies. Currently, there is no adjuvant therapy that has been agreed upon as a standard of care. Results from prospective, multi-institutional phase II and III trials are awaited, along with advances in molecular targeted therapies and radiation techniques, which will better define treatment standards and improve outcomes in this group of diseases.

UR - http://www.scopus.com/inward/record.url?scp=84895873759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895873759&partnerID=8YFLogxK

U2 - 10.1016/j.semradonc.2014.01.001

DO - 10.1016/j.semradonc.2014.01.001

M3 - Article

VL - 24

SP - 94

EP - 104

JO - Seminars in Radiation Oncology

JF - Seminars in Radiation Oncology

SN - 1053-4296

IS - 2

ER -